Glycerol Phenylbutyrate News
Glycerol Phenylbutyrate currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Glycerol Phenylbutyrate with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine...
- Evidence level: L5
- Predicted indications (20):
- urea cycle disorder (98.7%)
- argininosuccinic aciduria (98.2%)
- carbamoyl phosphate synthetase I deficiency disease (97.9%)
- acute neonatal citrullinemia type I (97.2%)
- adult-onset citrullinemia type I (97.2%)
- citrullinemia, type II, adult-onset (97.1%)
- 3-methylcrotonyl-CoA carboxylase 1 deficiency (97.1%)
- hyperinsulinism-hyperammonemia syndrome (96.8%)
- hyperammonemic encephalopathy due to carbonic anhydrase VA deficiency (96.6%)
- hyperargininemia (95.0%)
- citrullinemia (94.3%)
- citrin deficiency (93.5%)
- neonatal intrahepatic cholestasis due to citrin deficiency (92.7%)
- benign neoplasm of adrenal gland (90.8%)
- hyperammonemia due to N-acetylglutamate synthase deficiency (89.0%)
- familial apolipoprotein C-II deficiency (86.3%)
- polycystic kidney disease 3 with or without polycystic liver disease (83.1%)
- acute intermittent porphyria (81.3%)
- renal-hepatic-pancreatic dysplasia (79.6%)
- autosomal ichthyosis syndrome with fatal disease course (79.5%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.